Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego found the cost for the 10 “highest spend” medications in Medicare Part D rose almost one-third between 2011 and 2015. In the same time period, the number of patients treated with at least one of these medications also declined 32 percent.
Fewer patients receive the medications that the federal government is spending the most money on. For patients using the drugs without the benefit of subsidies, the average out-of-pocket cost for one of these 10 medications increased from $375 in 2011 to $1,366 in 2015, according to Jonathan Watanabe, PharmD, PhD, associate professor at UCSD.
The highest spend list in 2015: the top 10 drugs and conditions
- Lepidasvir/Sofosbuvir (hepatitis C)
- Insulin glargine (diabetes)
- Rosuvastatin calcium (cardiovascular disease)
- Fluticasone/Salmeterol (asthma and chronic obstructive pulmonary disease)
- Tiotropium bromide (chronic obstructive pulmonary disease)
- Sitagliptin phosphate (diabetes)
- Lenalidomide (blood cancers)
- Esomeprazole magnesium (dyspepsia, gastroesophageal reflux)
- Pregabalin (epilepsy, neuropathic pain, generalized anxiety disorder)
- Adalimumab (arthritis, Crohn’s disease)
Some of these are widely used and advertised. Rrosuvastatin marketed as Crestor, one of a class of statins prescribed for treating high cholesterol. Esomeprazole sells under the brand name Nexium and used to reduce stomach acid and prevent ulcers. Adalimumab marketed as Humira for arthritis and other conditions. Only one medication was a generic drug, atorvastatin, the generic version of the brand name Lipitor.
This is worrisome since the aging US population means more and more Americans will be using the Medicare system for their pharmaceutical needs. The number of Medicare beneficiaries will grow from 59 million in 2017 to 81 million in 2030, compounded by a declining worker-to-Medicare beneficiary ratio.
At this time, one in every six dollars spent in Medicare is on medications. And spending on expensive, specialty medications will likely grow with more approved drugs and a larger population that requires them. The study concludes, “since Medicare Part D is funded by enrollee paid premiums in addition to Congressional appropriations from general revenue, Part D enrollees may expect to face higher premiums on top of increasing copayments or coinsurance payments.”
It’s the Most Wonderful Time of the Year, to Review Your Story
The Two Character Differentials to Propel Yourself into the Future
Becoming Your Future You: Now!
5 Leadership Books You Must Read in 2019
Retirement Plans Disappear When Parents And The Kids Return Home
The Workplace Is No Place for Inappropriate Touching
Holiday Gifts for the Sales Rockstar in Your Life
6 Questions Business Owners Should Answer Before Selling Their Business
Behind Every Shaper, There’s a Hero
How To Create Equity In The Workplace
Equities13 hours ago
How Do Bitcoin Futures Affect the Price?
Development13 hours ago
Advisors: Break Out of Your Echo Chamber
Development13 hours ago
The Power of Thoughtful Client Gifts
Equities2 days ago
These Oil Stocks Are Ticking Time Bombs
Building Smarter Portfolios2 days ago
The Market’s Wild Ride
Human Performance2 days ago
5 Simple Ways to Improve Your Productivity At Work
Equities3 days ago
Bubble, Meet Pin; It’s Just the Beginning of the Downslide
Market Strategist3 days ago
Don’t Be Boxed Into Style Boxes